CANDEL THERAPEUTICS INC

Candel Therapeutics is a clinical-stage biotechnology company whose core business model involves developing cancer therapies that require animal testing for regulatory approval and research. The company’s lead product candidates, including its oncolytic viral immunotherapies, are in clinical trials that followed preclinical studies conducted in animal models. This reliance on animal experimentation is inherent to its drug development pipeline.

The company’s operations fall under the commercial exploitation of animals, as its research and development activities are built upon the use of live animals in laboratory settings. While specific details on the scale or nature of its animal use are not publicly disclosed in its financial filings, the biopharmaceutical sector’s standard pathway for novel therapeutics necessitates extensive animal testing to demonstrate safety and efficacy before human trials. Candel Therapeutics has not published a formal animal welfare policy or alternative testing commitments that would mitigate this exclusionary practice.